Clinical Trial Update: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) [Phase 1]

View source ↗

Summary

Phase 1 first-in-human study of ML261, an autologous DLL3-targeted CAR T cell therapy, in relapsed/refractory small cell lung cancer and select neuroendocrine c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Gastroenteropancreatic Neuroendocrine Neoplasm
• Neuroendocrine Prostate Cancer
• Small Cell Lung Cancer

Drugs mentioned

• ML261

Snippet

Sponsor: Moonlight Bio, Inc | Conditions: Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) | Phase 1 | Status: NOT_YET_RECRUITING